ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency

12 Nov 2021 07:22:40 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results

10 Nov 2021 16:01:02 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021

09 Nov 2021 08:00:05 By Nasdaq GlobeNewswire

Ascendis Pharma A/S - Share Repurchase Program Update

08 Nov 2021 08:00:03 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10

03 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

15 Oct 2021 08:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting

30 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Share Repurchase Program

29 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks

22 Sep 2021 16:27:29 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Upcoming Investor Presentations

07 Sep 2021 17:09:33 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program

07 Sep 2021 16:59:54 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

01 Sep 2021 19:43:47 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

31 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

25 Aug 2021 16:12:26 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

25 Aug 2021 15:24:38 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

17 Aug 2021 16:17:20 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

06 Aug 2021 07:05:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update

06 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency

11 Jun 2021 17:57:46 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

28 May 2021 07:05:00 By Nasdaq GlobeNewswire